Lynn Anson-Cartwright
Overview
Explore the profile of Lynn Anson-Cartwright including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ugalde-Morales E, Wilf R, Pluta J, Ploner A, Fan M, Damra M, et al.
Am J Hum Genet
. 2025 Feb;
112(3):630-643.
PMID: 39999848
Transcriptome-wide association studies (TWASs) have the potential to identify susceptibility genes associated with testicular germ cell tumors (TGCTs). We conducted a comprehensive TGCT TWAS by integrating genome-wide association study (GWAS)...
2.
Glicksman R, Jiang D, Bedard P, Ye X, Anson-Cartwright L, Billfalk-Kelly A, et al.
Int J Radiat Oncol Biol Phys
. 2025 Jan;
PMID: 39778682
Purpose: The optimal management of patients with de novo clinical stage IIA/B (CSIIA/B) or relapsed CSIIA/B (Rel-CSIIA/B) seminoma remains debated because of a lack of randomized evidence. Here, we sought...
3.
Chavarriaga J, Clark R, Atenafu E, Anson-Cartwright L, Warde P, Chung P, et al.
Eur Urol Focus
. 2024 Oct;
PMID: 39455407
Background And Objective: Studies in metastatic nonseminomatous germ-cell tumor (NSGCT) suggest that the presence of teratomatous elements in the primary tumor is a risk factor for poor survival. Many guidelines...
4.
Chavarriaga J, Mousa A, Atenafu E, Anson-Cartwright L, Langleben C, Jewett M, et al.
Urol Oncol
. 2024 Aug;
42(12):455.e1-455.e8.
PMID: 39191550
Introduction: Primary retroperitoneal lymph node dissection (pRPLND) is a treatment option for clinical stage (CS) II testicular germ cell tumors (TGCTs) and CS I with retroperitoneal relapse. Increasing raw lymph...
5.
Mousa A, Anson-Cartwright L, Atenafu E, Jewett M, Bedard P, Jiang D, et al.
BJU Int
. 2024 Jul;
134(4):622-629.
PMID: 38967557
Objectives: To compare the outcomes and treatment burden of primary retroperitoneal lymph node dissection (pRPLND) alone versus pRPLND + adjuvant chemotherapy (AC) in patients with pathological stage II (PSII) non-seminomatous...
6.
Chavarriaga J, Atenafu E, Mousa A, Langleben C, Anson-Cartwright L, Jewett M, et al.
Eur Urol Oncol
. 2024 Jan;
7(5):1034-1041.
PMID: 38278693
Background: Open retroperitoneal lymph node dissection (O-RPLND) is the accepted standard surgical approach to treat retroperitoneal nodal disease in testis cancer. Increasingly, robotic RPLND (R-RPLND) is being performed due to...
7.
Boormans J, Sylvester R, Anson-Cartwright L, Glicksman R, Hamilton R, Hahn E, et al.
Eur Urol Oncol
. 2023 Nov;
7(3):537-543.
PMID: 37951820
Background: The relapse rate in patients with clinical stage I (CSI) seminomatous germ cell tumor of the testis (SGCTT) who were undergoing surveillance after radical orchidectomy is 4-30%, depending on...
8.
Bobrowski A, Anson-Cartwright L, Kuhathaas K, Jiang D, Chung P, Bedard P, et al.
J Urol
. 2022 Aug;
208(6):1250-1258.
PMID: 35997696
Purpose: Tumor markers alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase assume a key role in the management of testicular germ cell tumors. While alpha-fetoprotein and human chorionic gonadotropin have modest...
9.
Grasso C, Popovic M, Isaevska E, Lazzarato F, Fiano V, Zugna D, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Jun;
31(9):1769-1779.
PMID: 35700037
Background: Testicular germ cell tumors (TGCT), histologically classified as seminomas and nonseminomas, are believed to arise from primordial gonocytes, with the maturation process blocked when they are subjected to DNA...
10.
Gariscsak P, Anson-Cartwright L, Atenafu E, Jiang D, Chung P, Bedard P, et al.
Eur Urol Open Sci
. 2022 May;
40:46-53.
PMID: 35638085
Background: We have recommended active surveillance as the preferred management option for clinical stage I (CSI) testicular germ cell tumors (GCTs) since 1980. Over time, the recommended intensity of surveillance...